药物性DNA去甲基化恢复DLBCL中SMAD1表达与肿瘤抑制信号
在弥漫性大B细胞淋巴瘤(DLBCL)中,TGF-β/SMAD1信号轴因SMAD1启动子高甲基化而失活。去甲基化药物地西他滨(DAC)可恢复SMAD1表达,使细胞对TGF-β诱导的凋亡敏感,并在多种异种移植模型中逆转肿瘤生长,包括患者来源的原位异种移植模型。
要点
- DLBCL中SMAD1启动子高甲基化导致TGF-β信号通路阻断。
- DAC恢复SMAD1表达并增强TGF-β诱导的凋亡。
- DAC在SMAD1敲除细胞中效应减弱,支持机制特异性。
核心结论
- 药物性DNA去甲基化可恢复DLBCL中SMAD1表达并重建肿瘤抑制信号。
研究设计与样本
- 使用DLBCL细胞系和患者样本,结合基因组编辑、皮下及原位异种移植模型和患者来源原位异种移植模型。
主要发现
- DLBCL细胞系和患者样本中SMAD1启动子CpG富集区高甲基化阻断TGF-β信号。
- DAC恢复SMAD1表达,使细胞对TGF-β诱导的凋亡敏感。
- DAC在异位和原位模型中逆转初始SMAD1阴性细胞系的生长。
- DAC效应在SMAD1敲除细胞系中减弱。
- DAC在患者来源原位异种移植模型中恢复SMAD1表达并减少肿瘤负荷。
关键数值与推荐
- TGF-β/TGF-βRII/SMAD1信号轴在>85%的DLBCL患者中失活。
临床怎么用
- 去甲基化药物可能通过恢复SMAD1表达为DLBCL提供治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The sphingosine-1-phosphate (S1P) receptor S1PR2 and its downstream adaptor Gα13 are recurrently mutationally inactivated in the germinal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL) and are silenced by the S1PR2 repressor FOXP1 in the activated B-cell like subtype of the disease. Loss of S1PR2 signaling relieves the germinal center confinement that is maintained by an S1P gradient and allows cells to resist S1P-induced apoptosis. We have shown previously that S1PR2 expression is induced in normal B cells through a newly described transforming growth factor-β (TGF-β)/TGF-βRII/SMAD1 signaling axis that is inactivated in >85% of DLBCL patients. DLBCL cell lines lacking S1PR2, TGFBRII, or SMAD1 as the result of genomic editing all have a strong growth advantage in vitro, as well as in subcutaneous and orthotopic xenotransplantation models. Here, we show that the TGF-β signaling pathway in DLBCL is blocked at the level of SMAD1 in DLBCL cell lines and patient samples by hypermethylation of CpG-rich regions surrounding the SMAD1 transcription start site. The pharmacologic restoration of SMAD1 expression by the demethylating agent decitabine (DAC) sensitizes cells to TGF-β-induced apoptosis and reverses the growth of initially SMAD1- cell lines in ectopic and orthotopic models. This effect of DAC is reduced in a SMAD1-knockout cell line. We further show that DAC restores SMAD1 expression and reduces the tumor burden in a novel patient-derived orthotopic xenograft model. The combined data lend further support to the concept of an altered epigenome as a major driver of DLBCL pathogenesis.
引用
- Stelling A, Wu CT, Bertram K, et al. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma. Blood Adv. 2019. PMID: 31648327. doi:10.1182/bloodadvances.2019000210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。